[{"id":"5c88c63c-d256-4f58-81e6-5b70704df6d0","acronym":"","url":"https://clinicaltrials.gov/study/NCT06632262","created_at":"2025-02-26T15:04:35.295Z","updated_at":"2025-02-26T15:04:35.295Z","phase":"Phase 2","brief_title":"A Phase 2 Clinical Study of ABSK061 and ABSK043","source_id_and_acronym":"NCT06632262","lead_sponsor":"Abbisko Therapeutics Co, Ltd","biomarkers":" HER-2 • FGFR2 • FGFR3","pipe":"","alterations":" ","tags":["HER-2 • FGFR2 • FGFR3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABSK043 • lavengratinib (ABSK061)"],"overall_status":"Recruiting","enrollment":" Enrollment 202","initiation":"Initiation: 11/13/2024","start_date":" 11/13/2024","primary_txt":" Primary completion: 11/30/2029","primary_completion_date":" 11/30/2029","study_txt":" Completion: 06/30/2030","study_completion_date":" 06/30/2030","last_update_posted":"2024-11-19"},{"id":"934d3478-921a-4635-9f03-493d15ba270a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05244551","created_at":"2022-02-17T18:22:17.151Z","updated_at":"2024-07-02T16:36:00.316Z","phase":"Phase 1","brief_title":"A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05244551","lead_sponsor":"Abbisko Therapeutics Co, Ltd","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 mutation • FGFR2 fusion • FGFR3 mutation • FGFR3 fusion","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation • FGFR2 fusion • FGFR3 mutation • FGFR3 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lavengratinib (ABSK061)"],"overall_status":"Recruiting","enrollment":" Enrollment 85","initiation":"Initiation: 06/30/2022","start_date":" 06/30/2022","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2022-11-16"}]